The invention relates to a method for producing 2,3,5-trimethyl benzoquinone or a compound containing 2,3,5-trimethyl benzoquinone, the method comprising the following steps: Oxidation of 2,3,6-trimethylphenol with oxygen or an oxygen-containing gas in a two-or multi-phase reaction medium in the presence of a catalyst or catalyst system containing at least one copper (II)-halide to a mixture containing 2,3,5-trimethyl benzoquinone, characterized in that the reaction medium contains water and at least one secondary aliphatic acyclic alcohol having 6 or more, preferably 7 or more, carbon atoms.

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

The present invention relates to new compounds for immunogenic treatment of cancer. The compounds can be administered as a single agent or in combination with an anticancer drug including modulators of other immune pathways, especially immune checkpoint inhibitors that target CTLA-4, PD-1, and PD-L1 proteins. The compounds can produce neoantigens through irreversible protein binding in cancer cells and generate immune response.

The present invention relates to new compounds for immunogenic treatment of cancer. The compounds can be administered as a single agent or in combination with an anticancer drug including modulators of other immune pathways, especially immune checkpoint inhibitors that target CTLA-4, PD-1, and PD-L1 proteins. The compounds can produce neoantigens through irreversible protein binding in cancer cells and generate immune response.

The present invention relates to a method of preparing ortho substituted phenols from 2,5-dimethylfuran and propargyl ethers in the presence of a gold(I) complex. It is particularly advantageous to use 2,5-dimethylfuran as this offers an ecological beneficial synthesis of said ortho substituted phenols.

The present invention relates to a method of preparing ortho substituted phenols from 2,5-dimethylfuran and propargyl ethers in the presence of a gold(I) complex. It is particularly advantageous to use 2,5-dimethylfuran as this offers an ecological beneficial synthesis of said ortho substituted phenols.

A method of producing thymoquinone and/or thymohydroquinone in Monarda by growing Monarda with elevated levels of carvacrol and/or thymol in the fresh plant tissue and vigorous growth, harvesting the Monarda, leaving the Monarda to senesce in the presence of oxygen and extracting the thymoquinone and/or thymohydroquinone from the senesced tissue.

A method of producing thymoquinone and/or thymohydroquinone in Monarda by growing Monarda with elevated levels of carvacrol and/or thymol in the fresh plant tissue and vigorous growth, harvesting the Monarda, leaving the Monarda to senesce in the presence of oxygen and extracting the thymoquinone and/or thymohydroquinone from the senesced tissue.

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.